At Incyte, our research is grounded in the rigorous pursuit of scientific excellence and the conviction that the advancement of basic science can drive the discovery of innovative medicines for patients. Our dedicated researchers are focused on transforming the treatment of cancer, and our product portfolio is expanding.

OVERVIEW OF OUR PORTFOLIO

Molecular Targets
17

Clinical Candidates
19

Portfolio

Filter By:
Filters
 

Updated as of October 30, 2018

1. Jakafi marketed by Incyte in the US; ruxolitinib licensed to Novartis ex-US 2. Patients with intermediate or high-risk myelofibrosis 3. Patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 4. European rights to Iclusig licensed from ARIAD 5. In collaboration with AstraZeneca  6. In collaboration with MacroGenics 7. In collaboration with Merck 8. Co-development with Calithera 9. Discovery alliance with Agenus 10. Worldwide rights to baricitinib licensed to Lilly: approved as Olumiant in multiple territories globally for certain patients with moderate to severe rheumatoid arthritis 11. Worldwide rights to capmatinib licensed to Novartis

Clinical Trials

We currently have a number of clinical trials underway in oncology. Incyte-sponsored studies and investigator-sponsored trials can be found at www.IncyteClinicalTrials.com.

Incyte also supports significant independent research aimed at advancing the study of our products. A team of professionals scrutinizes all proposals submitted to Incyte for scientific merit and alignment with Incyte’s research goals. If you are interested in submitting a research proposal, please contact us at ist.incyte.com.

Learn more about our target molecules currently in clinical development>

For Investigator Initiated Research (IIR) conducted outside of the US, please complete your submission at iir.incyte.com.

For questions about Investigator Initiated Research (IIR) conducted outside of the US, please contact Incyte at Global_IIR@incyte.com.